Project Grant K08AR082457
Award Date
5/7/25
Completion Date
4/30/30
Dollars Obligated
$156K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Indianapolis, IN 46202, USA
Similar Awards
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) has awarded a $383,570 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to Trustees of Indiana University, doing business as Indiana University Indianapolis. The grant, titled "Delineating the Contribution of Muscle Wasting to Tumor Progression," aims to better understand the relationship between skeletal muscle wasting and tumor progression in cancer patients. The...
This federal Project Grant award, funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is provided to Trustees of Indiana University, doing business as Indiana University Indianapolis, to conduct research on targeting the gene KLF10 to prevent cancer-associated muscle loss. The $239,239 award, with a period of performance from September 18, 2023 to August 31, 2024, aims...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to investigate the role of the protein FGF21 in mediating musculoskeletal wasting associated with metastatic colorectal cancer (CRC). The $423,084 award to the Trustees of Indiana University, doing business as Indiana University Indianapolis, will fund a 5-year study to: 1) examine how FGF21 impacts bone loss in advanced CRC, 2) determine the mechanisms by which FGF21...
The National Cancer Institute (NCI) awarded a $198,103 Project Grant (CFDA 93.395 - Cancer Treatment Research) to New York University (NYU) School of Medicine to conduct research on the role of the immune microenvironment in melanoma bone metastasis. The goal of this 2-year project is to better understand how melanoma cells infiltrate and modify the bone microenvironment, as well as how they communicate with immune cells and resist immunotherapy. The researchers will utilize preclinical murine...
This $146,816 federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will support research training and investigation into the role of the muscle circadian clock as a modifier of cancer cachexia. The key objectives are to: 1) Define the stage of cancer cachexia at which the muscle clock is disrupted and examine the relationship between clock disruption...
This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.396 Cancer Biology Research program), supports research to investigate the impact of cancer on the vascular and lymphatic systems of the intestine, and how this contributes to the development of cancer-induced cachexia. The $502,563 grant awarded to Northwestern University aims to determine if deficiencies in the lymphatic and vascular endothelium are a significant underlying cause of cancer-induced cachexia,...
This $279,354 federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support a research study to evaluate the use of denosumab and sequential zoledronic acid therapy to prevent bone loss after acute spinal cord injury (SCI). The study aims to replicate previous findings on the efficacy of denosumab in preventing bone loss after SCI, while also...
This $515,244 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports a 5-year research and training plan to determine the role of brain-derived CCN3 in bone and marrow fat metabolism. The principal investigator, Dr. Muriel Babey, will conduct in vitro and in vivo studies to examine how the dose and levels of circulating CCN3 affect bone formation,...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $575,021 to The Johns Hopkins University to conduct research focused on predicting the occurrence of cancer in patients with idiopathic inflammatory myositis (IIM) and determining how the emergence and elimination of cancer impact IIM clinical outcomes. The research aims to...
This Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) provides $1,396,152 to the University of Chicago to investigate the role of the protein BNIP3 and mitophagy (selective autophagy of mitochondria) in muscle atrophy associated with pancreatic ductal adenocarcinoma (PDAC) cancer cachexia. The key objectives are to: 1) examine how BNIP3 promotes atrophy of muscle fibers by reducing mitochondrial mass, and how restoring different BNIP3...